Orsini Partners With Priovant to Support LISRAYA Access
ELK GROVE VILLAGE, Illinois, Aug 28, 2026 Orsini announced that it will serve as a specialty pharmacy partner for...
rare disease
Advertisement
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
iECURE Reports 74% Reduction in OTC-HOPE Crises
Philadelphia – August 27, 2026 iECURE, Inc. presented updated clinical data from the ongoing OTC-HOPE Phase 1/2 trial of...
FDA Approves Janssen’s Imaavy for Rare Blood Disorder
SILVER SPRING, MARYLAND, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) injection for...
Daiichi Sankyo, AstraZeneca Advance Datroway in Phase 3 Urothelial Cancer Trial
Tokyo, August 26, 2026 Daiichi Sankyo announced that the first patient has been dosed in TROPION-Urothelial04, a global Phase...
Advertisements
INmune Bio Advances Ebstrocel Toward EU Marketing Filing
BOCA RATON, Fla., Aug. 26, 2026 INmune Bio Inc. has advanced Ebstrocel™ toward potential European commercialization after submitting two...
Rhythm Pharmaceuticals Wins Japan Approval for IMCIVREE
BOSTON, August 24, 2026 Rhythm Pharmaceuticals, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...
PTC Therapeutics Highlights Sephience PKU Data at SSIEM 2026
Warren, New Jersey, August 24, 2026 PTC Therapeutics, Inc. announced that new clinical and real-world evidence for Sephience™ (sepiapterin)...
Johnson & Johnson Wins FDA Approval for IMAAVY in wAIHA
Spring House, Pennsylvania, U.S. | August 24, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration...
Werewolf Therapeutics and Ambros Announce $150M Merger
Waltham, Massachusetts, USA, and San Diego, California, USA, August 21, 2026 Werewolf Therapeutics and Ambros Therapeutics have announced a...
Advertisement
